Abstract Background Inflammatory Bowel Diseases (IBD) are multifactorial and debilitating diseases that significantly impact patients’ quality of life. As it is known, they involve an altered immune system. For this reason, patients with IBD have an increased risk of developing other chronic immune disorders, including chronic rhinosinusitis (CRS). The coexistence of these two conditions can undoubtedly affect patients’ life and disease history. This study aims to define the prevalence of CRS in IBD patients and assess how it affects their quality of life. Methods We conducted a prospective, observational, monocentric pilot study. in which we enrolled consecutive IBD under biological therapy. We collected clinical, demographic, and disease history data. Four questionnaires were administered to the patients: the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), EuroQol 5 Dimension 5 Level (EQ-5D-5L), the Short-Form- 36 (SF-36), and the SNOT-22 questionnaire to identify subjective symptoms of CRS. According to the SNOT-22 score, patients were divided into two groups: patients without/mild CRS (group 1, SNOT-22 <30 points) and patients with moderate/severe CRS (group 2, SNOT-22>30 points). Results We enrolled 50 IBD patients, of which 48% were affected by ulcerative colitis (UC) and 52% were affected by Crohn’s Disease (CD). Among them, 42% (n=21) of patients were naive to biological therapy, while 48% had failed at least two lines of biological therapy. We observed no statistically significant differences in the mean values of the score of SNOT-22 between naive and multi-failure patients (30.1 and 28.5, respectively, p=0.76). Dividing patients based on the SNOT-22 score, 42% were part of group 1 (absent or mild CRS), and 58% were part of group 2 (moderate/severe CRS).CD patients of group 2 had a significantly higher disease activity, defined according to the Harvey-Bradshaw Index (HBI), compared to group 1 (mean value of 2.3 vs 0.48, p=0.008).We did not observe statistically significant differences in Full Mayo Score between group 1 and group 2 UC patients. The median VAS EQ-5D-5L was compared between Groups 1 and 2 showing a lower score in patients with moderate/severe CRS (66.6 vs. 81.3, p = 0.0019). Conclusion CRS is frequent in IBD patients. Those with both conditions have reduced quality of life, more severe symptoms, and worse disease characteristics than those without CRS. Level of some cytokines can induce alterations of gastrointestinal motility in gastrointestinal disorders, due to increased intestinal barrier damage. However, our findings are preliminary, and further studies, clinical evaluations, and specialized laboratory investigations are needed to better understand the gut-lung axis.
Read full abstract